| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1136/ARD.2008.101766 |
| P8608 | Fatcat ID | release_7kugxf5ucjf3ji6j5lx3opcfqu |
| P698 | PubMed publication ID | 19103632 |
| P50 | author | Guillermo Ruiz-Irastorza | Q37830875 |
| Manuel Ramos-casals | Q42646201 | ||
| Munther A. Khamashta | Q73418907 | ||
| P2093 | author name string | P Brito-Zeron | |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| antimalarial | Q521616 | ||
| systematic review | Q1504425 | ||
| P304 | page(s) | 20-28 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review | |
| P478 | volume | 69 |
| Q34085682 | 25(OH) vitamin D serum values and rheumatoid arthritis disease activity (DA S28 ESR) |
| Q48588705 | A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires |
| Q90767384 | A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires |
| Q98735895 | A Review of the Dermatological Manifestations of Coronavirus Disease 2019 (COVID-19) |
| Q41926759 | A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus |
| Q45707377 | Absence of the lysosomal protein Limp-2 attenuates renal injury in crescentic glomerulonephritis |
| Q90594140 | Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes |
| Q36221407 | American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis |
| Q96304889 | An update on the management of antiphospholipid syndrome |
| Q34184151 | Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort |
| Q39150067 | Antimalarial myopathy in a systemic lupus erythematosus patient with quadriparesis and seizures: a case-based review. |
| Q64956251 | Antimalarials - are they effective and safe in rheumatic diseases? |
| Q41916380 | Antimalarials as a risk factor for elevated muscle enzymes in systemic lupus erythematosus |
| Q41919852 | Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark. |
| Q35756040 | Antiphospholipid Syndrome during pregnancy: the state of the art |
| Q55891386 | Antiphospholipid syndrome |
| Q91390119 | Antiphospholipid syndrome - an update |
| Q53093982 | Antithrombotic treatment for stroke associated with antiphospholipid antibodies. |
| Q99237635 | Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment? |
| Q90585191 | Area-Level Predictors of Medication Nonadherence Among US Medicaid Beneficiaries With Lupus: A Multilevel Study |
| Q35800364 | Autophagy in autoimmune disease |
| Q37832082 | Autophagy modulation for cancer therapy |
| Q36398762 | Autophagy regulation in the development and treatment of breast cancer |
| Q33893517 | B cell TLRs and induction of immunoglobulin class-switch DNA recombination |
| Q46364779 | Belimumab for systemic lupus erythematosus: a practice-based view |
| Q34455827 | Belimumab for the treatment of systemic lupus erythematosus |
| Q104559093 | COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease |
| Q90496530 | COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression |
| Q36153524 | Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry |
| Q43885994 | Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study |
| Q56907410 | Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients |
| Q49349531 | Causes and predictors of mortality in biopsy-proven lupus nephritis: the Sarawak experience |
| Q90415557 | Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management |
| Q87393398 | Chapter 12: Lupus nephritis |
| Q56966244 | Characterization of damage in Portuguese lupus patients: analysis of a national lupus registry |
| Q38223293 | Childhood onset systemic lupus erythematosus: how is it different from adult SLE? |
| Q36869519 | Chinese Herbal Medicine (Zi Shen Qing) for Mild-to-Moderate Systematic Lupus Erythematosus: A Pilot Prospective, Single-Blinded, Randomized Controlled Study |
| Q90939644 | Chloroquine Is Effective for Maintenance of Remission in Autoimmune Hepatitis: Controlled, Double-Blind, Randomized Trial |
| Q38360827 | Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases |
| Q55208303 | Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. |
| Q26827797 | Chloroquine and hydroxychloroquine for cancer therapy |
| Q34342236 | Chloroquine cardiomyopathy - a review of the literature |
| Q34198175 | Chloroquine cardiomyopathy: beyond ocular adverse effects |
| Q37627829 | Chloroquine inhibits human CD4+ T-cell activation by AP-1 signaling modulation. |
| Q36956142 | Chloroquine interference with hemoglobin endocytic trafficking suppresses adaptive heme and iron homeostasis in macrophages: the paradox of an antimalarial agent |
| Q47218712 | Chronicity index, especially glomerular sclerosis, is the most powerful predictor of renal response following immunosuppressive treatment in patients with lupus nephritis. |
| Q53618640 | Circulating CXCR5+CD4+helper T cells in systemic lupus erythematosus patients share phenotypic properties with germinal center follicular helper T cells and promote antibody production. |
| Q38766335 | Clinical and serological features distinguish patients with incomplete lupus classification from systemic lupus erythematosus patients and controls |
| Q38133017 | Clinical aspects of autoimmune rheumatic diseases |
| Q47133837 | Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey. |
| Q51165596 | Comparison of plasma vitamin D levels in patients with Sjögren's syndrome and healthy subjects. |
| Q47441501 | Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus. |
| Q38650606 | Concerns of patients with systemic lupus erythematosus and adherence to therapy - a qualitative study |
| Q38168179 | Connective tissue disease in pregnancy. |
| Q41540102 | Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis |
| Q36443689 | Contemporary treatment of systemic lupus erythematosus: an update for clinicians. |
| Q97644054 | Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen |
| Q38222914 | Correlation between serum 25(OH)D values and lupus disease activity: an original article and a systematic review with meta-analysis focusing on serum VitD confounders |
| Q40161775 | Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study. |
| Q54218397 | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. |
| Q38818425 | Current status and future prospects for the treatment of antiphospholipid syndrome |
| Q57789918 | Cytokine production by activated plasmacytoid dendritic cells and natural killer cells is suppressed by an IRAK4 inhibitor |
| Q92646159 | Decreased expression of TIGIT in NK cells correlates negatively with disease activity in systemic lupus erythematosus |
| Q92118099 | Dermatologists' Adherence to the Latest Recommendations for Screening of Hydroxychloroquine Retinopathy in Saudi Arabia: Cross-Sectional Study |
| Q37453947 | Developments in the clinical understanding of lupus |
| Q37804548 | Drug Monitoring in Systemic Lupus Erythematosus: A Systematic Review |
| Q47143263 | Drug utilization and therapy provision patterns by prescriber types among patients with systemic lupus erythematosus in Korea |
| Q40047389 | Drugs used in incident systemic lupus erythematosus - results from the Finnish nationwide register 2000-2007. |
| Q49835073 | Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus |
| Q36126483 | Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus |
| Q50222848 | Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort |
| Q50065429 | Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study. |
| Q98736014 | Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19 |
| Q89483209 | Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers |
| Q36257051 | Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis |
| Q96231744 | Efficacy and safety of chloroquine plus prednisone for the treatment of autoimmune hepatitis in a randomized trial |
| Q41930370 | Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus |
| Q51607670 | Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study. |
| Q37673346 | Elevated expression of TIGIT on CD3+CD4+ T cells correlates with disease activity in systemic lupus erythematosus |
| Q44250901 | Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom |
| Q52562276 | Emerging role of semaphorin-3A in autoimmune diseases. |
| Q34187282 | European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies |
| Q36672583 | Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine |
| Q92026856 | Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues |
| Q41927491 | Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus |
| Q47557743 | Factors associated with health-related quality of life in Peruvian patients with systemic lupus erythematosus. |
| Q34169570 | Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII). |
| Q37978291 | Glucocorticoid use and abuse in SLE. |
| Q50215099 | Health-related quality of life in systemic lupus erythematosus: a longitudinal study on the impact of problematic support and self-efficacy |
| Q97075375 | Hippocampal Atrophy in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations |
| Q42692514 | How can we reduce the risk of serious infection for patients with systemic lupus erythematosus? |
| Q90157934 | Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy |
| Q41915986 | Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis |
| Q41930905 | Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study |
| Q41919912 | Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. |
| Q95830612 | Hydroxychloroquine as antiviral prophylaxis for exposed caregivers to Covid-19: An urgent appraisal is needed |
| Q39062828 | Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients |
| Q49383523 | Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience |
| Q95633060 | Hydroxychloroquine effects on psoriasis: a systematic review and a cautionary note for COVID-19 treatment |
| Q24186197 | Hydroxychloroquine for systemic lupus erythematosus in adults |
| Q97646016 | Hydroxychloroquine in Dermatology and Beyond: Recent Update |
| Q38285841 | Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases |
| Q38029146 | Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects |
| Q39031764 | Hydroxychloroquine in systemic lupus erythematosus (SLE). |
| Q37854742 | Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy |
| Q41927831 | Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). |
| Q99726452 | Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence |
| Q58608546 | Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an in vivo mouse model of antiphospholipid syndrome |
| Q55507790 | Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. |
| Q33747286 | Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug |
| Q34003992 | Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression |
| Q41929433 | Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. |
| Q58608203 | Hydroxychloroquine retinopathy - implications of research advances for rheumatology care |
| Q34162739 | Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus |
| Q37158591 | Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus |
| Q51382288 | Hydroxychloroquine-induced acute psychosis in a systemic lupus erythematosus female. |
| Q88400696 | Hydroxychloroquine-induced hypoglycaemia in non-diabetic renal patient on peritoneal dialysis |
| Q26782822 | Hydroxychloroquine-related retinal toxicity |
| Q41934841 | Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome |
| Q51393905 | Hypovitaminosis D and response to cholecalciferol supplementation in patients with autoimmune and non-autoimmune rheumatic diseases. |
| Q37991390 | Immunomodulatory effects of antimicrobial agents. Part II: antiparasitic and antifungal agents |
| Q28548561 | Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease |
| Q41917416 | Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study |
| Q39578523 | Implementation of recommendations for the screening of hydroxychloroquine retinopathy: poor adherence of rheumatologists and ophthalmologists |
| Q35840758 | Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study |
| Q39556212 | In vitro activity of immunosuppressive drugs against Plasmodium falciparum |
| Q35911531 | Inactive disease and remission in childhood-onset systemic lupus erythematosus |
| Q38149856 | Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies |
| Q51152425 | Inflammation-related cardiovascular morbidity : Pathophysiology and therapy |
| Q26796413 | Inflammatory etiopathogenesis of systemic lupus erythematosus: an update |
| Q45771233 | Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National Cohort Study |
| Q38557048 | Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics |
| Q99610879 | Insights on the evidence of cardiotoxicity of hydroxychloroquine prior and during COVID-19 epidemic |
| Q38182646 | Interplay of infections, autoimmunity, and immunosuppression in systemic lupus erythematosus |
| Q97533087 | Is hydroxychloroquine beneficial for COVID-19 patients? |
| Q33667694 | Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis |
| Q26849746 | Juvenile systemic lupus erythematosus: review of clinical features and management |
| Q37821052 | Lupus and pregnancy: integrating clues from the bench and bedside |
| Q38446941 | Lupus nephritis management guidelines compared |
| Q38608138 | Lupus nephritis: an update |
| Q36194783 | Macroautophagy is deregulated in murine and human lupus T lymphocytes |
| Q26774815 | Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives |
| Q33730536 | Management of cardiovascular complications in systemic lupus erythematosus |
| Q39272988 | Management of cardiovascular risk in systemic lupus erythematosus: a systematic review |
| Q37705657 | Management of systemic lupus erythematosus during pregnancy: challenges and solutions. |
| Q87774110 | Management of very high risk pregnancy with secondary anti-phospholipid syndrome and triple positivity to the anti-phospholipid antibodies |
| Q44393048 | Managing comorbidities of inflammatory rheumatic diseases |
| Q44913899 | Managing lupus nephritis in pregnant women: comment on the article by Hahn et al. |
| Q35622999 | Manipulating autophagic processes in autoimmune diseases: a special focus on modulating chaperone-mediated autophagy, an emerging therapeutic target |
| Q36220831 | Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus |
| Q89603158 | Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology |
| Q94565351 | Medically explained symptoms: a mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases |
| Q64085964 | Megakaryocytic dysfunction in immune thrombocytopenia is linked to autophagy |
| Q91675894 | Mesenchymal Stem Cells: Allogeneic MSC May Be Immunosuppressive but Autologous MSC Are Dysfunctional in Lupus Patients |
| Q36177195 | Metabolic regulation of organelle homeostasis in lupus T cells |
| Q50861922 | Metabolic syndrome in Chinese patients with systemic lupus erythematosus: no association with plasma cortisol level. |
| Q38176594 | Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy |
| Q39553303 | Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine |
| Q92715340 | Myeloid disorders after autoimmune disease |
| Q33908254 | Naja naja atra Venom Protects against Manifestations of Systemic Lupus Erythematosus in MRL/lpr Mice |
| Q38026787 | New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. |
| Q90412368 | New therapeutic strategies in systemic lupus erythematosus management |
| Q38225438 | Optimizing pharmacotherapy of systemic lupus erythematosus: the pharmacist role |
| Q92715682 | Overlap Syndrome Involving Systemic Lupus Erythematosus and Autoimmune Hepatitis in Children: A Case Report and Literature Review |
| Q39198671 | Pathogenesis and management of antiphospholipid syndrome |
| Q35998510 | Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention |
| Q60173972 | Pediatric lupus nephritis |
| Q38630775 | Pharmacologic management of neuropsychiatric lupus |
| Q96028621 | Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research |
| Q38156069 | Pragmatic approaches to therapy for systemic lupus erythematosus |
| Q38600390 | Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort. |
| Q37350893 | Predictors of major infections in systemic lupus erythematosus |
| Q41929732 | Predictors of survival in Chinese patients with lupus nephritis |
| Q38255384 | Pregnancy outcomes in patients with systemic lupus erythematosus: a retrospective review of 62 pregnancies at a single tertiary center in South Korea |
| Q43900414 | Premature coronary heart disease in SLE: can we prevent progression? |
| Q38149850 | Premature coronary heart disease in systemic lupus erythematosus: what risk factors do we understand? |
| Q38851096 | Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care |
| Q38794847 | Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population? |
| Q39027911 | Prevention of thrombosis in antiphospholipid syndrome |
| Q38076460 | Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions. |
| Q52316454 | Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. |
| Q92488644 | Protective effect of hydroxychloroquine on rheumatoid arthritis-associated atherosclerosis |
| Q39997361 | Quality of life in systemic lupus erythematosus: description in a cohort of French patients and association with blood hydroxychloroquine levels |
| Q47760514 | Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus |
| Q39208441 | Rate of Adverse Effects of Medium- to High-Dose Glucocorticoid Therapy in Systemic Lupus Erythematosus: A Systematic Review of Randomized Control Trials |
| Q38010014 | Recent progress in the treatment of lupus nephritis |
| Q57945954 | References |
| Q34315879 | Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. |
| Q87467570 | Renal involvement in antiphospholipid syndrome |
| Q36186103 | Reno-protective effect and mechanism study of Huang Lian Jie Du Decoction on lupus nephritis MRL/lpr mice |
| Q41929591 | Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI). |
| Q41931972 | Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI). |
| Q56336954 | Reversal of loss of bone mass in old mice treated with mefloquine |
| Q100395540 | Revisiting the cardiovascular risk of hydroxychloroquine in RA |
| Q52836583 | S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). |
| Q38852499 | SLE: the changing prognosis |
| Q40668710 | Secular trends of pregnancies in women with inflammatory connective tissue disease |
| Q58727146 | Seizures as a rare adverse effect of chloroquine therapy in systemic lupus erythematosus patients: a case report and literature survey |
| Q38033120 | Semaphorin 3A - a marker for disease activity and a potential putative disease-modifying treatment in systemic lupus erythematosus |
| Q51160485 | Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone. |
| Q88477714 | Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016 |
| Q38169778 | Synthetic antimalarial drugs and the triggering of psoriasis - do we need disease-specific guidelines for the management of patients with psoriasis at risk of malaria? |
| Q37807147 | Systemic Lupus Erythematosus: Safe and Effective Management in Primary Care |
| Q43134475 | Systemic lupus erythematosis: the basics of nursing care |
| Q44213235 | Systemic lupus erythematosus |
| Q89919135 | Systemic lupus erythematosus |
| Q38131100 | Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment |
| Q37921757 | Systemic lupus erythematosus in Hispanics |
| Q93193261 | Systemic lupus erythematosus: Diagnosis and clinical management |
| Q38191835 | Systemic lupus erythematosus: a therapeutic challenge for the XXI century |
| Q34498515 | Systemic lupus erythematosus: review of synthetic drugs |
| Q38866356 | Systemic lupus erythematosus: still a challenge for physicians |
| Q27687098 | Targeting dendritic cell function during systemic autoimmunity to restore tolerance |
| Q97521704 | Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients |
| Q48332079 | The Cutaneous Spectrum of Lupus Erythematosus. |
| Q92956352 | The Role of NETosis in Systemic Lupus Erythematosus |
| Q37721612 | The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis |
| Q49787347 | The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients |
| Q43490656 | The challenge of pregnancy for patients with SLE. |
| Q48081474 | The chequered history of the antiphospholipid syndrome. |
| Q39882878 | The lysosome among targets of metformin: new anti-inflammatory uses for an old drug? |
| Q37947108 | The role of antimalarial agents in the treatment of SLE and lupus nephritis |
| Q37924056 | The role of autophagy in cancer: therapeutic implications |
| Q35257433 | The role of autophagy induced by tumor microenvironment in different cells and stages of cancer |
| Q38235741 | The role of dead cell clearance in the etiology and pathogenesis of systemic lupus erythematosus: dendritic cells as potential targets |
| Q37737799 | The role of dendritic cells in the pathogenesis of systemic lupus erythematosus |
| Q38062341 | The treatment of systemic lupus proliferative nephritis |
| Q37236107 | Therapeutic targeting of autophagy in disease: biology and pharmacology |
| Q38561490 | Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases |
| Q64897464 | Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. |
| Q38205079 | Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. |
| Q35621012 | Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches |
| Q84697085 | Treatment of cutaneous lupus erythematosus |
| Q38126540 | Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy |
| Q35456519 | Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies |
| Q38271125 | Treatment of severe lupus nephritis: the new horizon. |
| Q37974990 | Treatment of systemic lupus erythematosus: new advances in targeted therapy |
| Q47208836 | Trends in use of hydroxychloroquine during pregnancy in systemic lupus erythematosus patients from 2001 to 2015. |
| Q35915182 | Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation? |
| Q27005906 | Unmet medical needs in systemic lupus erythematosus |
| Q52654857 | Update on Antiphospholipid Syndrome: Ten Topics in 2017. |
| Q41935321 | Use of antimalarials in dermatology |
| Q48129331 | Very delayed lupus nephritis: a report of three cases and literature review. |
| Q46395898 | Vitamin D and cutaneous lupus erythematosus: effect of vitamin D replacement on disease severity |
| Q39027915 | What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies? |
| Q37236049 | Why can't we find a new treatment for SLE? |
| Q85589119 | [Lupusnephritis] |
| Q85714424 | [Personalized medicine in the choice of conventional immunosuppressants and disease modifying antirheumatic drugs] |
| Q84789923 | [Rheumatic diseases with primary onset in young adults: spondyloarthritis and connective tissue diseases] |
| Q84566584 | [Systemic lupus erythematosus. A problem based approach] |
Search more.